Clinical trial · Interventional
Erector Spinae Plane Block Versus Serratus Plane Block for Breast Surgery
Erector Spinae Plane Block Versus Serratus Plane Block on Postoperative Opioid Consumption for Modified Radical Mastectomy and Axillary Lymph Node Dissection
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Serratus plane block (SPB) was first described in 2013 by Blanco and designed to primarily block the thoracic intercostal nerves. And this block provides sufficient analgesia lateral anterior and posterior part of thoracic wall.Erector Spinae Plane Block (ESPB) is a newly described and effective interfascial plane block for thoracic and abdominal surgery. It was first described by Forero et al. in 2016, effectiveness being reported in four cases. The aim of this study is to compare Serratus plane block and erector spinae plane block on postoperative pain in patients undergoing modified radical mastectomy and axillary lymph node dissection
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Postoperative Pain | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bupivacaine Hcl 0.25% Inj | Drug | — | UNRESOLVED |
| Bupivacaine HCl Inj 0.25% | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- ultrasound guided serratus plane block
- description
- Ultrasound Guided Serratus Plane Block 30 ml %0.25 Bupivacaine
- interventionNames
- Drug: Bupivacaine Hcl 0.25% Inj
- type
- ACTIVE_COMPARATOR
- label
- ultrasound guided erector spinae plane block
- description
- Ultrasound Guided Erector Spinae Plane Block 20 ml %0.25 Bupivacaine
- interventionNames
- Drug: Bupivacaine HCl Inj 0.25%
Primary outcomes (1)
- measure
- Opioid Consumption
- timeFrame
- First 24 hours
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * American Society of Anesthesiologist's physiologic state I-III patients * undergoing breast cancer surgery * 18-65 years Exclusion Criteria: * chronic pain * bleeding disorders * renal or hepatic insufficiency * patients on chronic non-steroidal anti-inflammatory medications * emergency cases * coagulopathy
References
Publications (0)
Data not yet available